| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 29, 2023 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP" WEXFORD, Pa. and MIAMI, Oct. 31, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. ("Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (NASDAQ:BHSE), a special purpose acquisition company ("Bull Horn"). In connection with the Business Combination, the combined company has been renamed "Coeptis Therapeutics Holdings, Inc." (the "Company") and its public shares and warrants are expected to commence trading on the Nasdaq G
SNAP-CAR therapy provides a highly programmable therapeutic platform designed to potentially target many tumor types, including hematological malignancies and solid tumors WEXFORD, Pa., Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.
Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial
424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
SC 13G - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)
SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)
SC 13D - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)